Financiere des Professionnels Fonds d investissement inc. Has $10.41 Million Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Financiere des Professionnels Fonds d investissement inc. lessened its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 22.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 20,018 shares of the medical research company's stock after selling 5,910 shares during the quarter. Financiere des Professionnels Fonds d investissement inc.'s holdings in Thermo Fisher Scientific were worth $10,414,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the company. Legacy Investment Solutions LLC acquired a new position in Thermo Fisher Scientific during the 3rd quarter valued at about $26,000. Peterson Financial Group Inc. acquired a new position in Thermo Fisher Scientific in the third quarter valued at approximately $27,000. Barrett & Company Inc. acquired a new position in Thermo Fisher Scientific in the fourth quarter valued at approximately $28,000. Missouri Trust & Investment Co acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at $29,000. Finally, Endeavor Private Wealth Inc. acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at $30,000. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Up 1.4 %

Shares of NYSE:TMO traded up $7.17 during trading on Thursday, hitting $538.03. 1,967,770 shares of the company were exchanged, compared to its average volume of 2,101,941. The stock has a market cap of $205.80 billion, a price-to-earnings ratio of 32.55, a P/E/G ratio of 2.91 and a beta of 0.77. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific Inc. has a fifty-two week low of $493.30 and a fifty-two week high of $627.88. The firm has a fifty day moving average price of $548.10 and a two-hundred day moving average price of $568.36.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. As a group, research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific declared that its Board of Directors has approved a share repurchase plan on Friday, November 15th that permits the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization permits the medical research company to purchase up to 2% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company's board of directors believes its stock is undervalued.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 0.32%. The ex-dividend date is Friday, March 14th. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.39. Thermo Fisher Scientific's payout ratio is 9.44%.

Insiders Place Their Bets

In related news, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $530.26, for a total transaction of $5,302,600.00. Following the transaction, the chief executive officer now directly owns 111,192 shares of the company's stock, valued at approximately $58,960,669.92. The trade was a 8.25 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the company's stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total transaction of $175,677.00. Following the completion of the transaction, the executive vice president now owns 16,363 shares in the company, valued at approximately $9,582,009.17. This represents a 1.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 20,125 shares of company stock valued at $11,231,699 over the last 90 days. 0.34% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on TMO shares. Evercore ISI cut their target price on Thermo Fisher Scientific from $630.00 to $620.00 and set an "outperform" rating on the stock in a research note on Thursday, October 24th. UBS Group increased their price target on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the company a "buy" rating in a research report on Friday, January 31st. Raymond James reiterated an "outperform" rating and issued a $667.00 target price (up from $650.00) on shares of Thermo Fisher Scientific in a report on Monday, February 3rd. Stifel Nicolaus dropped their price target on Thermo Fisher Scientific from $680.00 to $665.00 and set a "buy" rating on the stock in a research report on Thursday, October 24th. Finally, Citigroup raised their price target on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock a "neutral" rating in a research report on Friday, January 31st. Four investment analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, Thermo Fisher Scientific has an average rating of "Moderate Buy" and an average target price of $658.00.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.